# Patient-Trial Match Report

*Generated: 2026-01-05 18:29:40*

## Patient Profile

- **Age**: 45
- **Sex**: Female
- **Cancer Type**: melanoma
- **Biomarkers**: BRAF V600E

**Clinical Description**:
> 45-year-old female with metastatic cutaneous melanoma, BRAF V600E mutated. Primary on left lower extremity (Breslow 2.8mm) resected 2023. Developed lung and subcutaneous metastases 8 months later. First-line dabrafenib/trametinib achieved partial response but progressed at 14 months. Second-line nivolumab/ipilimumab combination - mixed response, eventually progressed with new splenic lesions. Currently well-appearing with good functional status. LDH elevated (312). Looking for novel combinations or emerging targets. No brain mets on most recent MRI.

- **Location Preference**: United States

## Search Summary

- **Search terms used**: 9
- **Total trials evaluated**: 75
- **Excluded by fast filter**: 29
- **LLM scored**: 46

## ðŸŸ¢ HIGH Likelihood (15 trials)

### [NCT04971499](https://clinicaltrials.gov/study/NCT04971499)

**A Study of Dapansutrile Plus Pembrolizumab in Patients With PD-1 Refractory Advanced Melanoma**

- **Sponsor**: April Salama, M.D.
- **Phase**: Phase 1/Phase 2
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Histologically confirmed melanoma
- Unresectable Stage IV melanoma
- Age is 45, which is above the minimum (18)
- ECOG status is 0
- Has received anti-PD-1/PD-L1 therapy (nivolumab/ipilimumab) as part of the most recent line of therapy
- Progressed on anti-PD-1/PD-L1 therapy within 6 months
- Meets measurable disease requirements based on RECIST criteria
- Has available archival tumor tissue sample

**? Uncertainties:**
- Organ function lab results to confirm adequate organ function based on inclusion criteria
- Confirmation of prior adverse events resolution to â‰¤ grade 1
- Verification of any additional specifics regarding additional treatments received or required timelines

**Assessment:**
> The patient has metastatic melanoma which aligns with the trial's focus on melanoma. The patient's history shows that they have progressed on anti-PD-1 therapy, which is a requirement for the trial. With a favorable ECOG status and age criteria, the patient meets most other criteria, but there are some uncertainties regarding organ function and prior adverse events.

---

### [NCT03743298](https://clinicaltrials.gov/study/NCT03743298)

**Phase 1B Trial of AV-MEL-1 (Autologous Dendritic Cells Loaded With Autologous Tumor Antigens) With Anti-PD-1 Checkpoint Inhibitors in Metastatic Melanoma**

- **Sponsor**: Aivita Biomedical, Inc.
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Age is 45 (above 18)
- ECOG status is 0 (greater than 70 KPS)
- Diagnosed with metastatic melanoma
- PD-L1 is at 60%
- Measurable metastatic lesions (lung and subcutaneous)
- No active brain metastases

**Assessment:**
> The patient's disease is metastatic melanoma, which matches the trial's focus. The patient is also previously treated with BRAF inhibitors and anti-PD-1 antibodies, which aligns with the trial's eligibility for previously treated patients. All criteria match without significant contradictions.

---

### [NCT05562791](https://clinicaltrials.gov/study/NCT05562791)

**Pilot Study of 68Gallium PSMA-PET/CT in Patients With Metastatic Urothelial Carcinoma or Melanoma**

- **Sponsor**: Memorial Sloan Kettering Cancer Center
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Patient has histologically confirmed metastatic melanoma
- ECOG status is 0
- Patient is 45 years old

**Assessment:**
> The patient's cancer type (metastatic melanoma) matches the trial's indication for the melanoma cohort. The patient is previously treated but does not violate any treatment line requirements stated for eligible participants. All basic eligibility criteria are met, especially ECOG status and age.

---

### [NCT06608511](https://clinicaltrials.gov/study/NCT06608511)

**Liquid Biomarker Study in Melanoma and Non-Melanoma Skin Cancers**

- **Sponsor**: University of Wisconsin, Madison
- **Phase**: N/A
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Confirmed diagnosis of melanoma
- Age is 45, which is â‰¥18 years
- ECOG status is 0, indicating good functional status
- No brain metastases

**Assessment:**
> The patient's confirmed diagnosis of melanoma aligns with the trial's conditions studied. The patient is also older than the minimum age requirement and has a good ECOG status with no brain metastases, fulfilling the eligibility criteria.

---

### [NCT07148245](https://clinicaltrials.gov/study/NCT07148245)

**Characterization of the Symptom Experience of Patients With Cutaneous Melanoma Receiving Immune Checkpoint Inhibitor Therapy**

- **Sponsor**: University of California, San Francisco
- **Phase**: N/A
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Age: 45
- Sex: female
- Cancer type: melanoma
- Biomarkers: BRAF V600E
- ECOG status: 0
- PD-L1: 60%
- No brain metastases

**Assessment:**
> The patient's cancer type is melanoma, which matches the trial conditions. The patient is over 18 years of age, has a good ECOG status, and has a PD-L1 of 60%, which qualifies her for immune checkpoint inhibitor therapy. There are no unknown disqualifying factors.

---

### [NCT03474497](https://clinicaltrials.gov/study/NCT03474497)

**UCDCC#272: A Phase I/II Study of Intralesional IL-2, Hypofractionated Radiotherapy, and Pembrolizumab in Patients Refractory to Standard-of-Care PD-1/PD-L1 Checkpoint Blockade**

- **Sponsor**: Megan Daly, MD
- **Phase**: Phase 1/Phase 2
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Age: 45 years old
- Sex: female
- Cancer type: melanoma
- ECOG status: 0
- PD-L1: 60%
- Prior therapies: failed PD-1/PD-L1 checkpoint blockade therapy

**? Uncertainties:**
- Presence of a candidate treatment lesion (not specified)
- Life expectancy (not explicitly verified)
- Adequate organ function labs (not provided)

**Assessment:**
> The patient's cancer type of melanoma matches the trial's target indications. The patient is over 18, has an ECOG status of 0, and has failed previous PD-1/PD-L1 therapies. However, there are uncertainties regarding the presence of a treatment lesion and organ function that need to be clarified, though they are not major conflicts.

---

### [NCT05503797](https://clinicaltrials.gov/study/NCT05503797)

**A Phase 2 Master Protocol to Assess the Efficacy and Safety of FORE8394, an Inhibitor of BRAF Class 1 and Class 2 Alterations, in Participants With Cancer Harboring BRAF Alterations**

- **Sponsor**: Fore Biotherapeutics
- **Phase**: Phase 2
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Patient diagnosed with BRAF V600E mutated melanoma
- Patient is 45 years old
- ECOG status is 0
- Patient has received all available standard therapy
- Patient has good functional status
- Patient has an archival tissue sample available

**? Uncertainties:**
- LDH level is elevated but its specific impact on trial eligibility is unclear

**Assessment:**
> The patient's cancer type of melanoma with a BRAF V600E mutation aligns with the trial's focus on BRAF alterations. The patient has prior treatment as required by the criteria. There is a minor uncertainty regarding the elevated LDH, but overall, the evidence strongly supports eligibility.

---

### [NCT05970497](https://clinicaltrials.gov/study/NCT05970497)

**A Phase 1/2, Open-Label, Multi-Center, Dose Escalation and Expansion Study of KB707 in Subjects With Locally Advanced or Metastatic Solid Tumor Malignancies**

- **Sponsor**: Krystal Biotech, Inc.
- **Phase**: Phase 1/Phase 2
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Metastatic cutaneous melanoma
- ECOG performance status of 0
- PD-L1 level of 60%
- No brain metastases
- Age of 45
- Prior therapies included anti-PD-1 (nivolumab) and anti-CTLA-4 (ipilimumab)
- BRAF V600E mutation

**Assessment:**
> The patient has advanced melanoma (stage IV) and has previously been treated with one anti-PD-1 treatment (nivolumab) and has also progressed on BRAF/MEK inhibitor therapy, satisfying the inclusion criteria for cohorts 5 and 6. The patient's age, ECOG status, and lack of brain metastases meet the other eligibility requirements. No significant conflicts or uncertainties are present.

---

### [NCT06975293](https://clinicaltrials.gov/study/NCT06975293)

**Open-label, Non-randomized, Multi-cohort, Phase 1b/2 Trial Investigating the Safety, Tolerability, and Antitumor Activity of STC-15 (a METTL3 Inhibitor) as a Part of Combination Therapy With Toripalimab in Participants With Selected Advanced Cancers**

- **Sponsor**: STORM Therapeutics LTD
- **Phase**: Phase 1/Phase 2
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Patient has metastatic melanoma as confirmed by clinical details.
- ECOG performance status of 0 is acceptable.
- LDH is elevated but does not exclude eligibility.
- Patient has documented disease progression on the prior therapy (nivolumab/ipilimumab).
- Patient has the ability to swallow, retain, and absorb oral medication.

**Assessment:**
> The patient's metastatic melanoma aligns with the trial's conditions, and she has the ECOG status and documented disease progression needed for eligibility. Additionally, she has previously received anti-PD-1 therapy. No conflicts or uncertainties were identified.

---

### [NCT02012699](https://clinicaltrials.gov/study/NCT02012699)

**Integrated Cancer Repository for Cancer Research**

- **Sponsor**: University of Nebraska
- **Phase**: N/A
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Diagnosis/history of cancer: melanoma
- ECOG status: 0
- Age: 45
- PD-L1: 60%
- No brain metastases

**Assessment:**
> The patient's cancer type (melanoma) matches the trial conditions (melanoma included). The patient is previously treated, which aligns with the trial's inclusion for previously treated patients. All standard eligibility criteria are met.

---

### [NCT04314401](https://clinicaltrials.gov/study/NCT04314401)

**Cancer Moonshot Biobank Research Protocol**

- **Sponsor**: National Cancer Institute (NCI)
- **Phase**: N/A
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Patient has melanoma, which is studied in the trial.
- Patient has ECOG status of 0, which is acceptable.
- Patient is over 13 years old and meets the age requirement.
- Patient has PD-L1 of 60%, which is above the required threshold.

**Assessment:**
> The patient's melanoma diagnosis matches the trial conditions, and the patient's ECOG status, age, and PD-L1 levels are all compliant with eligibility criteria. There are no conflicting factors or uncertainties regarding the treatment line, as the patient is currently looking for novel combinations due to prior treatments.

---

### [NCT05225428](https://clinicaltrials.gov/study/NCT05225428)

**Video Education With Result Dependent dIsclosure**

- **Sponsor**: Dana-Farber Cancer Institute
- **Phase**: Not Applicable
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Patient has a diagnosis of melanoma, which is included in the trial conditions studied.
- Patient is 45 years old, meeting the age criteria of â‰¥ 18 years.
- Patient's ECOG status is 0, indicating good functional status.

**? Uncertainties:**
- The patient's prior treatments could be a factor, but there is no specific mention of whether this trial is for treatment-naive or previously treated patients.
- The patient's ability to understand spoken or written English or Spanish is not explicitly stated.

**Assessment:**
> The patient's disease matches the trial indication as she has melanoma, and her age and ECOG status meet the eligibility criteria. However, uncertainties regarding treatment line and language comprehension create minor doubts.

---

### [NCT05538130](https://clinicaltrials.gov/study/NCT05538130)

**A PHASE 1A/B OPEN-LABEL MASTER STUDY OF PF-07799544 AS A SINGLE-AGENT AND IN COMBINATION WITH OTHER TARGETED AGENTS IN PARTICIPANTS WITH ADVANCED SOLID TUMORS**

- **Sponsor**: Pfizer
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Diagnosis of advanced/metastatic melanoma
- Disease progressed following last prior treatment (ipilimumab + nivolumab)
- Evidence of a BRAF V600 mutation
- ECOG status 0
- No brain metastases

**? Uncertainties:**
- Current organ function (LDH elevated but no other organ function labs provided)

**Assessment:**
> The patient's cancer type (metastatic melanoma) matches the trial's focus on advanced solid tumors, and she meets the treatment line requirement since she has progressed after prior therapies. Additionally, her BRAF V600E mutation aligns with the trial's biomarker requirement. Other criteria are met as well, leading to a high confidence in her eligibility despite an uncertainty regarding her organ function.

---

### [NCT06150664](https://clinicaltrials.gov/study/NCT06150664)

**A Phase 1, Open-Label, Multiple-Ascending Dose Study of the Safety and Tolerability of CTX-8371 in Patients With Advanced Malignancies**

- **Sponsor**: Compass Therapeutics
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Cancer type is malignant melanoma, which is included in the trial conditions.
- Patient has a confirmed diagnosis of metastatic melanoma.
- Patient has progressed after treatment with PD-1/PD-L1 therapy (nivolumab/ipilimumab).
- Patient has received prior therapy with BRAF/MEK inhibitors (dabrafenib/trametinib).
- ECOG status is 0, meeting the performance status criterion.

**? Uncertainties:**
- Patient's liver function tests are not provided, making it uncertain if they meet the adequate hepatic function criteria.
- Patient's renal function criteria are not provided, making it uncertain if they meet the adequate renal function criteria.

**Assessment:**
> The patient's cancer type matches the study indication and they have prior treatments aligning with the eligibility criteria. Treatment lines are appropriate and ECOG status is acceptable. However, there are uncertainties regarding liver and renal function tests.

---

### [NCT06910657](https://clinicaltrials.gov/study/NCT06910657)

**A First-in-human, Phase I, Multi-center, Open-label, Dose-escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Evidence of Antitumor Activity of IDOV-Immune in Adult Participants With Advanced Solid Tumors**

- **Sponsor**: ViroMissile, Inc.
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Age is 45, which is > 18 years
- ECOG status is 0, which is â‰¤ 1
- Patient has advanced solid tumor (melanoma) that has progressed despite standard therapy
- PD-L1 expression is 60%, which is â‰¥ 50%
- No active or untreated CNS metastases are present

**? Uncertainties:**
- Adequate organ and bone marrow function cannot be confirmed from provided information
- Details on prior therapies' toxicities are not fully specified

**Assessment:**
> The patient's condition matches the trial's focus on advanced solid tumors, specifically melanoma, and the provided information supports eligibility for previously treated patients with no current brain metastases. There are minor uncertainties regarding organ function and prior therapy-related toxicities, but these do not significantly undermine the overall eligibility assessment.

---

## ðŸŸ¡ MEDIUM Likelihood (1 trials)

### [NCT05267626](https://clinicaltrials.gov/study/NCT05267626)

**A Phase 1/2, First-in-Human, Open Label, Dose Escalation and Expansion Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2RÎ± Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer**

- **Sponsor**: Aulos Bioscience, Inc.
- **Phase**: Phase 1/Phase 2
- **Status**: Recruiting
- **Confidence**: 65%

**âœ“ Supporting Factors:**
- Patient has cutaneous melanoma.
- Patient has BRAF mutation (BRAF V600E).
- ECOG status is 0.
- Patient has elevated PD-L1 (60%).
- No brain metastases.

**âœ— Potential Conflicts:**
- Patient has previously been treated with multiple therapies including dabrafenib, trametinib, nivolumab, and ipilimumab, which raises questions on the eligibility criteria related to prior treatment.

**? Uncertainties:**
- Radiographic progression timing relative to enrollment is unclear.
- LDH level is elevated (312), but it is uncertain if it exceeds the trial criteria of 2.5 x ULN.

**Assessment:**
> The patient has a type of cancer (cutaneous melanoma) that matches the trial's focus and has a relevant biomarker (BRAF V600E). However, the patient has a history of multiple prior therapies, which conflicts with the trial's requirement regarding previous treatments. Some uncertainties exist regarding radiographic progression and LDH levels.

---

## ðŸŸ  LOW Likelihood (1 trials)

### [NCT07223424](https://clinicaltrials.gov/study/NCT07223424)

**Patient Preference for Subcutaneous vs. Intravenous Immune Therapy (PSI-Immune)**

- **Sponsor**: Diwakar Davar
- **Phase**: Phase 2
- **Status**: Recruiting
- **Confidence**: 25%

**âœ“ Supporting Factors:**
- Patient has melanoma, which is included in the trial's conditions studied.
- ECOG status is 0, which indicates good functional status.

**âœ— Potential Conflicts:**
- Patient has received prior systemic therapies (nivolumab and ipilimumab) which does not meet the criteria for being treatment-naive as required for Cohort A-1 or Cohort A-2.

**? Uncertainties:**
- No specific details about the ability to receive nivolumab (no mention of prior allergic reactions).
- Uncertain eligibility based on organ function since lab values are not available.

**Assessment:**
> While the patient has melanoma, their history of previous treatments does not align with the trialâ€™s requirement for treatment-naive patients, leading to likely exclusion.

---

## Excluded (58 trials)

### Excluded by Fast Filter

| NCT ID | Reason |
|--------|--------|
| [NCT01174121](https://clinicaltrials.gov/study/NCT01174121) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT02670707](https://clinicaltrials.gov/study/NCT02670707) | Patient age 45 is above maximum age 21 |
| [NCT02693535](https://clinicaltrials.gov/study/NCT02693535) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT03803553](https://clinicaltrials.gov/study/NCT03803553) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT03851445](https://clinicaltrials.gov/study/NCT03851445) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT04079179](https://clinicaltrials.gov/study/NCT04079179) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT04166409](https://clinicaltrials.gov/study/NCT04166409) | Patient age 45 is above maximum age 21 |
| [NCT05009992](https://clinicaltrials.gov/study/NCT05009992) | Patient age 45 is above maximum age 39 |
| [NCT05313243](https://clinicaltrials.gov/study/NCT05313243) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT05684965](https://clinicaltrials.gov/study/NCT05684965) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT05828069](https://clinicaltrials.gov/study/NCT05828069) | Patient age 45 is below minimum age 180 |
| [NCT06074588](https://clinicaltrials.gov/study/NCT06074588) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT06582745](https://clinicaltrials.gov/study/NCT06582745) | Patient age 45 is above maximum age 30 |
| [NCT06585410](https://clinicaltrials.gov/study/NCT06585410) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT06712875](https://clinicaltrials.gov/study/NCT06712875) | Patient age 45 is above maximum age 26 |
| [NCT07023731](https://clinicaltrials.gov/study/NCT07023731) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT07070232](https://clinicaltrials.gov/study/NCT07070232) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT02485847](https://clinicaltrials.gov/study/NCT02485847) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT03254667](https://clinicaltrials.gov/study/NCT03254667) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT03420963](https://clinicaltrials.gov/study/NCT03420963) | Patient age 45 is above maximum age 40 |
| ... | *and 9 more* |

### Excluded by Eligibility Assessment

| NCT ID | Sponsor | Reason |
|--------|---------|--------|
| [NCT01638676](https://clinicaltrials.gov/study/NCT01638676) | University of Louisv | Prior treatment with Vemurafenib (excluded by trial criteria) |
| [NCT03567889](https://clinicaltrials.gov/study/NCT03567889) | Philogen S.p.A. | Patient has metastatic melanoma (IIIB), but the trial specifically targets Stage IIIB, IIIC, and IIID melanoma that is eligible for complete surgical resection of all metastases and requires surgically resectable disease. |
| [NCT04844528](https://clinicaltrials.gov/study/NCT04844528) | University of Utah | Patient has melanoma while the trial is studying CLL and non-melanoma skin cancers. |
| [NCT06112314](https://clinicaltrials.gov/study/NCT06112314) | Immunocore Ltd | Patient has prior systemic anticancer therapy for unresectable or metastatic melanoma which conflicts with the trial's requirement for treatment-naive patients. |
| [NCT06157099](https://clinicaltrials.gov/study/NCT06157099) | OHSU Knight Cancer I | Patient has metastatic melanoma (stage IV), while trial requires resected high-risk stage IIA, IIB, or IIIA melanoma. |
| [NCT06194929](https://clinicaltrials.gov/study/NCT06194929) | University of Utah | Trial includes patients with brain metastases, but the patient has no brain metastases |
| [NCT07015190](https://clinicaltrials.gov/study/NCT07015190) | IDEAYA Biosciences | Patient has melanoma while the trial is specifically for uveal melanoma (different disease type) |
| [NCT04474301](https://clinicaltrials.gov/study/NCT04474301) | M.D. Anderson Cancer | Patient has prior systemic therapies (dabrafenib, trametinib, nivolumab, ipilimumab) whereas the trial is likely for treatment-naive patients. |
| [NCT04697576](https://clinicaltrials.gov/study/NCT04697576) | Carlo Contreras | Patient has received multiple prior systemic therapies (dabrafenib, trametinib, nivolumab, ipilimumab), while trial appears to require patients to be treatment-naive. |
| [NCT05839912](https://clinicaltrials.gov/study/NCT05839912) | Craig L Slingluff, J | Patient has multiple metastatic sites beyond one lymph node, which does not match the trial's condition of having one clinically positive lymph node. |
| [NCT06466434](https://clinicaltrials.gov/study/NCT06466434) | M.D. Anderson Cancer | Patient has received multiple prior systemic therapies including ICB in the metastatic setting, which is excluded. |
| [NCT04899908](https://clinicaltrials.gov/study/NCT04899908) | Dana-Farber Cancer I | Patient does not have brain metastases, which are required for trial participation. |
| [NCT05868629](https://clinicaltrials.gov/study/NCT05868629) | Novartis Pharmaceuti | The trial explicitly excludes patients with melanoma. |
| [NCT05896839](https://clinicaltrials.gov/study/NCT05896839) | National Cancer Inst | Patient must be a kidney transplant recipient, but the patient is not reported as such. |
| [NCT04513028](https://clinicaltrials.gov/study/NCT04513028) | Kelly McMasters | Patient is not treatment-naive, having previously received multiple therapies including immunotherapy (nivolumab, ipilimumab). Trial requires treatment-naive or treatment no less than 6 months prior to enrollment. |
| [NCT05786924](https://clinicaltrials.gov/study/NCT05786924) | Institut de Recherch | Patient has melanoma; trial is studying NSCLC and other malignancies. |
| [NCT06902376](https://clinicaltrials.gov/study/NCT06902376) | UNC Lineberger Compr | Patient has BRAF V600E mutation, while trial requires BRAF V600E mutation-negative tumor |
| [NCT05704647](https://clinicaltrials.gov/study/NCT05704647) | M.D. Anderson Cancer | Trial includes only patients with active melanoma brain metastases, but the patient has no brain metastases. |
| [NCT06932757](https://clinicaltrials.gov/study/NCT06932757) | University of Miami | Patient has melanoma while trial is studying uveal melanoma. |
| [NCT07237100](https://clinicaltrials.gov/study/NCT07237100) | Kevin Kim, MD | Patient does not have an NF1 mutation required for the trial. |
| ... | ... | *and 9 more* |

## Search Terms Used

| Term | Source | Confidence |
|------|--------|------------|
| BRAF V600E | manual | 1.0 |
| BRAFV600E | manual | 0.9 |
| BRAF-V600E | manual | 0.9 |
| melanoma | manual | 1.0 |
| BRAF V600E melanoma | manual | 1.0 |
| BRAF V600E metastatic melanoma | llm | 0.9 |
| BRAF V600E cutaneous melanoma | llm | 0.9 |
| cutaneous melanoma | llm | 0.8 |
| BRAF V600E mutated | llm | 0.9 |

## Information That Would Improve Matches

The following patient data was not provided but would help refine eligibility assessment:

- **Organ function labs** (hematology, liver, renal) - required by all interventional trials
- **Life expectancy estimate** - many trials require â‰¥3 months
